In This Article:
NEW YORK, April 02, 2025--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the Company will be hosting an Analyst Day at the New York Stock Exchange in Lower Manhattan that will start at 10am on Monday, April 7, 2025.
The Company intends to focus the Analyst Day discussion on:
-
OST-HER2 program for human recurrent, fully resected lung metastatic osteosarcoma that is being positioned for Accelerated Approval in late 2025
-
OST-HER2 program for canine osteosarcoma that is being positioned for conditional approval in the second half of 2025, and plans for full approval
-
OST-HER2 data in breast cancer, and other human solid tumors to be pursued immediately after approval of OST-HER2 in osteosarcoma
Additionally, the Company will review the pipeline of assets being acquired from Ayala Pharmaceuticals, and potential of our tunable drug conjugates (tDC) & antibody drug conjugates (tADC) platform.
Event Information
| Title: |
|
| OS Therapies NYSE Analyst Day |
| Location: |
|
| New York Stock Exchange, 18 Broad St, New York, NY 10005 |
| Date: |
|
| April 7, 2025 @ 10am ET (arrive at 9:30am ET to allow security clearance) |
| Reservation: |
|
|
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.